Innocuité à long terme de l’apremilast jusqu'à 5 ans à partir de 15 études randomisées et contrôlées par placebo sur le psoriasis, le rhumatisme psoriasique et le syndrome de Behçet
Am J Clin Dermatol. 2023;24(5):809-820 doi: 10.1007/s40257-023-00783-7
This study confirms the safety of long-term apremilast use in patients with plaque PsO, active PsA, or oral ulcers associated with Behçet’s syndrome. In coming to this conclusion, investigators conducted a pooled analysis of apremilast data from 15 clinical studies with open-label extension phases, focusing on long-term safety.
Interestingly, exposure-adjusted incidence rate for serious events and events of special interest were low (< 1%) in patients treated with apremilast 30mg twice daily despite significant exposure. Overall, apremilast provides a therapeutic option with established long-term safety and a favourable benefit–risk profile for patients with PsA, PsO, or Behçet’s syndrome requiring chronic, systemic therapy.
Keywords:
